EP1763397A1 - System for manufacturing micro-spheres - Google Patents

System for manufacturing micro-spheres

Info

Publication number
EP1763397A1
EP1763397A1 EP05749229A EP05749229A EP1763397A1 EP 1763397 A1 EP1763397 A1 EP 1763397A1 EP 05749229 A EP05749229 A EP 05749229A EP 05749229 A EP05749229 A EP 05749229A EP 1763397 A1 EP1763397 A1 EP 1763397A1
Authority
EP
European Patent Office
Prior art keywords
micro
spheres
bubbles
jetting
production fluid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP05749229A
Other languages
German (de)
French (fr)
Inventor
Marcel R. Boehmer
Hendrik R. Stapert
Paulus C. Duineveld
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Koninklijke Philips NV
Original Assignee
Koninklijke Philips Electronics NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koninklijke Philips Electronics NV filed Critical Koninklijke Philips Electronics NV
Priority to EP05749229A priority Critical patent/EP1763397A1/en
Publication of EP1763397A1 publication Critical patent/EP1763397A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/02—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops
    • B01J2/06—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops in a liquid medium

Definitions

  • the invention pertains to a system for manufacturing micro-spheres from a production fluid.
  • the known system produces biodegradable microspheres, i.e. micro-spheres on the basis of ink-jet technology.
  • paclitaxel loaded PLGA microspheres of narrow size distribution and controlled diameter are manufactured.
  • the known system employs a drop-on-demand process or pressure assisted drop-on-demand for jetting a paclixatel PLGA mixture into an aqueous polyvinyl alcohol solution.
  • Microspheres having a narrow size distribution around ⁇ O ⁇ m ⁇ l ⁇ m have been produced. These micro-spheres are formed from a dichloroethane solution containing 3% of PLGA and 1.5% of paclitaxel. After making drops of this solution the dichloroethane is removed and solid particles containing a mixture of PLGA and paclitaxel remain.
  • An object of the invention is to provide a system to manufacturing micro- spheres having far smaller sizes than the size of the microspheres produced by the known system and also achieving narrow size distribution.
  • the invention is based on the insight mat starting from low concentration, i.e. in the range of 0.01% to 5%, from polymers monodisperse, dense polymer particles can be formed by inkjetting and subsequent removal of solvent. Good results are achieved in the range of polymer concentration of 0.01 to 3%. Particularly reliable formation of monodisperse microspheres is achieved in the range of polymer concentration of 0.01 to 2.9%.
  • the size of the micro-spheres bubbles is very small, notably micro-spheres having size in the range l-15 ⁇ m, with a small variation in volume of about 3% is achieved. Typically 5 ⁇ m sized micro-spheres are produced.
  • the production fluid is a solution of the constituting material, i.e.
  • the material(s) of which the microspheres are to be made in a solvent in other words: the constituent(s) of the final microspheres are dissolved in the production fluid.
  • the solvent in the production fluid should have a limited solubility in the receiving fluid with the receiving fluid. The solvent will slowly diffuse into the receiving fluid and subsequently evaporate, leading to shrinkage of the drops of the production fluid. Good results are achieved at solubilities around 1%, such as is the case for dichloroethane (DCE ) or dichloroomethane (DCM) in water.
  • DCE dichloroethane
  • DCM dichloroomethane
  • the production liquid contains a halogenated solvent which has a high density, such as dichloro-ethane and the receiving solution is aqueous.
  • halogenated solvents with a small solubility in water (about 0.8% for dichloroethane) and a high vapour pressure are preferred for slow and controlled removal from the drops of production fluid.
  • the constituents of the final microspheres are dissolved in the production fluid.
  • biodegradable polymers and (modified) phospholipids are preferred as carrier materials
  • drugs and imaging agents can be incorporated in the microspheres and targeted to markers of diseases expressed on blood vessel walls, such as markers for angiogenesis associated with tumours and markers for vulnerable plaques.
  • the excess stabilizer can be removed through a series of washing steps and the removal of the final remainders of the halogenated solvent can be established by lyophilization (freeze drying). It appears an essentially monodisperse distribution of small sized microspheres is achieved.
  • the jetting of the production fluid into the receiving fluid leads to better excellent separation of the individual micro-droplets when they leave the nozzle.
  • the manufacturing involves jetting of the production fluid at relatively high jetting rates, into a receiving fluid. It is found that at low polymer concentration in the production fluid, shrinkage of the droplet to essentially non-porous polymer micro-spheres occurs.
  • the production liquid has to be modified with a non-solvent for the shell forming material.
  • the production liquid can also be modified to include phospholipids rather than polymers or a combination of phospholipids and polymers.
  • the system for manufacturing micro-spheres is provided with a control system to operate the jetting in a pulsed fashion.
  • the control system control the application of excitation pulses to the jetting module.
  • Block shaped pulses achieve good results in that somewhat larger sized micro-spheres of a few tenths of nl volume are produced.
  • the jetting system is provided with several nozzles that can be individually controlled to adjust the sizes of the micro- bubbles from the respective nozzles.
  • these nozzles are controlled so that they all produce bubbles within a narrow size distribution.
  • the individual control of the individual nozzles then compensates for small differences between the nozzles. Notably, this is achieved by adjusting the electrical activation pulses applied to the nozzles.
  • the width of the volume distribution can be narrowed to about 3-5%. As more nozzles are employed, more micro-spheres can be produced per unit of time.
  • micro-spheres with a controlled porosity can be formed.
  • the reservoir is provided with a temperature control to cool the receiving fluid below its condensation temperature. Good results are achieved when the receiving liquid is cooled below room temperature, i.e. below 298K. Then, the production fluid is jetted in the form of droplets into the cooled receiving liquid, and may be stored for later use. When the temperature of the droplets is raised, the receiving fluid is evaporated and gas-filled micro-spheres are formed. Further a catalyst may be employed in the receiving liquid to initiate polymerization of the production fluid to enhance formation of stable micro-bubbles.
  • electro-magnetic radiation for example ultra-violet radiation of the bubbles leaving the nozzle by means of an irradiation module may be employed for photo-initiation of polymerization.
  • LCST lower critical solution temperature
  • UST upper critical solution temperature
  • An LCST is observed when precipitation of the polymer occurs at increasing temperatures.
  • the temperature of the receiving fluid is raised above the LCST and the polymer containing solution is jetted at temperature below the LCST.
  • Micro ⁇ spheres will then form due to the precipitation of the polymer within the well-defined droplets.
  • This approach is particular advantageous when use of halogenated receiving liquids is not allowed, or when lyophilization (freeze-drying) is not desired.
  • Example of a well- known polymer with an LCST is poly(N-isopropylacryl amide)(PNiPAAm).
  • the LCST of this polymer ( ⁇ 32 °C) can be easily tuned to relevant temperatures for clinical application (e.g. below or above 37 0 C) by copolymerisation with poly(acrylic acid) or more hydrophobic acrylates, depending on the LCST desired.
  • the ink-jet head is placed under the surface of the receiving liquid/air interface.
  • inkjetted droplets do not have to pass the air- liquid interface but will be injected directly into the receiving fluid.
  • the stabilizing action of polymers or surfactants present in the receiving liquid will be optimized leading to a stable emulsion of drops of the production fluid in the receiving liquid.
  • the stabilizer can be added to the production fluid, a suitable stabilizer is a phospholipid.
  • the production fluid has a higher density than the receiving liquid and the jet is in the direction of gravity, the droplet will continue to sink to the bottom of the container with their sedimentation velocity, from which they can be easily collected.
  • the production fluid has a lower density than the receiving liquid and the droplets are jetted in a direction such that the droplets float towards the surface of the receiving liquid without returning towards the nozzle.
  • the micro-spheres that are formed can then be collected at the surface of the receiving liquid.
  • the invention also relates to an ultra-sound contrast agent.
  • the use of apsherical microdroplets as an ultra-sound contrast agent is known per se from the US-patent US 5 606 973.
  • the ultra-sound contrast of the invention comprises essentially mono-disperse micro-bubbles filled with a gas or monodisperse microspheres filled with fluorocarbonliquid.
  • the micro-bubbles not only change the reflection of ultra sound, but also are able to resonate in the ultrasound field which yields harmonics.
  • Such a mono-disperse contrast agent is in particular advantageous to be employed in the form of a targeted contrast agent.
  • the targeted contrast agent selectively binds to specific receptors, e.g. adheres to vessel wall tissue.
  • the resonance frequency of selectively bound micro-bubbles is shifted with respect to the non- bound micro-bubbles.
  • the mono-disperse distribution of micro-bubbles leads to narrow line width of these resonances and hence the frequency shift can be detected. Hence, bound contrast agent can be accurately distinguished from unbound contrast agent.
  • Such gas filled bubbles can be prepared from a production fluid containing a halogenated solvent, a low concentration of shell forming biodegradable polymer, a second non-polar liquid with not too high a molecular weight which will allow for removal by lyophilization.
  • Biodegradable polymers are chosen that are insoluble in the receiving liquid, but also insoluble in the production fluid if the halogenated solvent has disappeared by diffusion into the receiving liquid followed by evaporation.
  • biodegradable polymers that can be used in the invention are biopolymers, such as dextran and albumin or synthetic polymers such as poly(L-lactide acid) (PLA)and certain poly(meth)acrylates polycaprolacton, polyglycolicacid Of particular importance are so-called (block)copolymers that combine the properties of both polymer blocks (e.g. hydrophobic and hydrophilic blocks).
  • random copolymers are poly(L-lactic-glycolic acid)(PLGA) and poly(d-lactic-l- lactic acid) Pd,lLA;
  • diblock copolymers are poly(ethylene glycol)-poly(L-lactide) (PEG-PLLA), poly(ethylene glycol) - poly(N-isopropylacryl amide)(PEG-PNiPAAm)and poly(ethylene oxide)- poly(propylene glycol) (PEO-PPO).
  • An example of a triblockcopolymer is poly(ethylene oxide)-poly(propylene glycol)-poly(ethyleneoxide) (PEO-PPO-PEO).
  • micro-spheres that result from this production liquid have a very good impermeability for water
  • the synthesis of such fluorinated polymer is known per se from the US-patent US 6 329 470.
  • the elasticity of the shell can be tuned by varying the polymer properties, the important parameters or the gel transition temperature and the maximum elongation before breakage of the a film made from the material will occur.
  • Micro-spheres filled with a liquid such as a fluorinated liquid, such as perfluorobromo-octane are not only useful for ultrasound but also for functional magnetic resonance imaging (fMRI).
  • a liquid such as a fluorinated liquid, such as perfluorobromo-octane
  • the technique of fMRI is generally disclosed in the Proc. Intl. Soc. mag. Reson. Med. 9(2001)659-660.
  • F magnetic resonance spectroscopy measurements can be made of tissue oxygenations, pharmacokinetics of fluorinated cancer drugs as mentioned per se in the Proc. Intl. Soc. mag. Reson. Med. 9(2001)497
  • They can be prepared as described above, except that fluorine containing non-polar liquid is chosen and that this liquid is not removed during lyophilization.
  • Micro-spheres can also be filled with drugs; drugs can be dissolved in an oil, and micro-spheres with a liquid core will be formed, or gaseous drugs can be incorporated by exposing micro-spheres to the gas containing the gaseous drug after lyophilization.
  • the drugs can be used for controlled release, for instance release by an ultrasound pulse to effectuate local delivery. This will be most efficient when targeted micro-spheres are used.
  • Radio-active compounds such as (activated/chelated) Holmium compounds for the treatment of liver malignancies are useful.
  • Holmium functions as a magnetic resonance contrast agent which induces Ti as well as T 2 contrast.
  • Holmium can made radioactive by irradiating with neutrons.
  • the radioactive isotopes of Holmium irradiate ⁇ - radiation (high-energy electronics) as well as ⁇ -radiation.
  • the ⁇ -radiation can be employed therapeutically to locally destroy tumours while the activity as magnetic resonance contrast agent enables monitoring of correct local application of the radioactive Holmium.
  • the ⁇ -emission can be detected by a gamma-camera to image the anatomy where the Holmium is applied.
  • Micro-spheres with non-radioactive Holmium are first formed and subsequently by irradiating with neutrons the Holmium in converted into radioactive Holmium isotopes in the micro-spheres.
  • the Holmium should not be released until it has lost its radioactivity.
  • Particle should be big enough to get trapped in the capillary bed and no fine micro-spheres should get a chance to circulate in the blood. For this reason a well controlled synthesis is required.
  • micro-spheres The typical size of the micro-spheres depends on the specific application. Preferred sizes range from 1 — 100 ⁇ m. For example micro-spheres for US imaging as blood- pool agents have most preferred diameters between 1- 10 ⁇ m. Most preferred diameters for Holmium encapsulated micro-spheres are within 15-40 ⁇ m.
  • Figure 1 shows a diagrammatic representation of a system for manufacturing micro-bubbles of the invention
  • Figure 2 shows the size distribution of inkjetted particle after washing with PVA, percentage of particle in 1 ⁇ m classes is given;
  • Figure 3 shows a SEM picture of PLA particles obtained according to the procedure described in Example 1 below and Figure 4 shows size distributions from examples 7 (0.1% plga) and 8 (0.1% plga, 0.3% cyclo-octane);
  • Figure 5 shows an example of microspheres made of an L_polylactide having a model diameter of 4.7 ⁇ m
  • Figure 6 shows an example of microspheres made of an L_polylactide having a model diameter of 4.5 ⁇ m.
  • FIG 1 shows the diagrammatic representation of a system for manufacturing micro-bubbles of the invention.
  • the system for manufacturing micro-bubbles comprises the reservoir 1 which contains the receiving fluid 11.
  • a jetting system 2 includes a nozzle 21 to eject of jet droplets of the production fluid 23 into the receiving fluid.
  • the nozzle 21 is provided with a piezo-electrical system 22 that applies pressure pulses to the nozzle to produce the droplets 24 from which the micro-spheres 25 form that assemble in this example at the bottom of the reservoir 1.
  • the nozzle 21 may be configured an ink-jetting head.
  • the jetting system 2 is also provided with a control unit 3 which applies electrical pulses to the piezo-electrical system 22.
  • the control unit in this way controls the operation of the jetting system to produce the droplets of the production fluid.
  • a cooling system 4 is provided, in this example in the form of a jacket 4 through which a cooling fluid, e.g. water, is passed from an inlet 41 to an outlet 42.
  • the cooling system operates to cool the receiving liquid to below room temperature.
  • the system for manufacturing micro-bubbles is provided with an ultraviolet radiation source 5, which emits a (pulsed) beam of ultraviolet radiation to the droplets of production fluid from the nozzle to cause photoinitiasation of polymerization in the droplets in order that micro-spheres are formed.
  • an ultraviolet radiation source 5 which emits a (pulsed) beam of ultraviolet radiation to the droplets of production fluid from the nozzle to cause photoinitiasation of polymerization in the droplets in order that micro-spheres are formed.
  • Example 1 preparation of 10 mm PLA particles
  • a 1% PLA (poly-DL-lactide, Aldrich) solution in dichloroethane was inkjetted, starting immediately after immersion of the ink jet head into an aqueous 1% PVA (15/79) solution in a fluorescence cuvet.
  • the initial drop diameter is about 50 ⁇ m as observed through the cuvet, which corresponds to a drop volume of 6.5*10-14 m3.
  • the sediment was redispersed and transferred to a glass sample bottle and stirred for one hour to remove the dichloroethane. The particles were washed 3 times with filtered (200 nm), deionised water.
  • a 3% PLA (poly-DL-lactide, Aldrich) solution in dichloroethane was inkjetted, starting immediately after immersion of the ink jet head into a aqueous 1% PVA solution in a fluorescence cuvet. After inkjetting for 20 minutes at 1500 Hz, the procedure was stopped. The sediment was redispersed and transferred to a glass sample bottle and stirred for one hour to remove the dichloroethane. The particles were washed 3 times with filtered (200 nm), deionised water. A sample was taken for microscopic examination, revealing well dispersed monodisperse spherical particles with a diameter of about 18 ⁇ m. Freeze drying did not change the particle size. The volume ratio between initial droplet volume and final particle size is 20, which is expected for a 5% solution if completely dense polymer particles would have formed. This indicates that remaining porosity is present in these prepared particles made from a 3% solution.
  • a 3% PLGA (PoIy-DL lacticde-co-glycolide (75:25), Aldrich) solution in dichloroethane was inkjetted, starting immediately after immersion of the ink jet head into a aqueous 1% PVA solution in a fluorescence cuvet. After inkjetting for 20 minutes at 1500 Hz, the procedure was stopped. The sediment was redispersed and transferred to a glass sample bottle and stirred for one hour to remove the dichloroethane. The particles were washed 3 times with filtered (200 nm), deionised water. A sample was taken for microscopic examination, revealing well dispersed monodispersed spherical particles with a diameter of about 18 mm.
  • Example 4 preparation of pla particles using continuous inkjet
  • a 1% solution of pla in dichloroethane was prepared and inkjetted into a 1% aqueous PVA 15/79 solution at a frequency of 14 kHz using a 50 ⁇ m nozzle. After evaporation of dichloroethane, washing and freeze-drying particles with an average diameter of 15.3 ⁇ m and a standard deviation of 2.7 ⁇ m were formed as quantified using image analysis of optical microscopy pictures.
  • a 1% solution of pla, 0.02% of holmium-acetylacetonate in dichloroethane was inkjetted into a 1% aqueous PVA (15/79) solution at a frequency of 14 kHz using a 50 ⁇ m nozzle.
  • the particles formed after evaporation of dichloroethane, washing and freeze- drying had an average diameter of 15.7 ⁇ m and a standard deviation of 2.6 ⁇ m as quantified using image analysis of optical microscopy pictures.
  • Example 6 Preparation of 12 mm plga particles by continuous inkjet A 1% solution of plga (75% lactic acid, 25% glycolic acid) in dichloroethane was prepared and inkjetted into a 1% PVA 15/79 solution at a frequency of 14 kHz using a 50 ⁇ m nozzle. The particles formed after evaporation of dichloroethane, washing and freeze- drying had an average diameter of 12.5 ⁇ m and a standard deviation of 2.3 ⁇ m as quantified using image analysis of optical microscopy pictures.
  • Example 7 preparation of 7 mm plga particles by continuous inkjet
  • a 0.1% solution of plga (75% lactic acid, 25% glycolic acid) in dichloroethane was prepared and inkjetted into a 1% PVA 15/79 solution at a frequency of 14 kHz using a 50 ⁇ m nozzle.
  • the particles formed after evaporation of dichloroethane, washing and freeze- drying had an average diameter of 6.8 ⁇ m and a standard deviation of 1.3 ⁇ m, as quantified using image analysis of optical microscopy pictures. The size distribution is indicated in Figure 4.
  • Example 9 preparation of lipid-coated capsules A 0.1% plga, 0.3% cyclooctane, 0.005% asolectin in dichloroethane was inkjetted into an aqueous PVA 15/79 solution at 12 kHz using a 50 ⁇ m nozzle. The dichloroethane was evaporated, the sample was washed and freeze dried, smooth capsules with a diameter of 7.5 ⁇ m were observed using SEM exhibiting a single hollow core.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Acoustics & Sound (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)

Abstract

System for manufacturing micro-spheres of a production fluid (23)containing a constituting material. The system comprises a reservoir (1) for holding a receiving fluid (11). There further is provided a jetting module (2) having at least one nozzle (21) for jetting the production fluid into the receiving fluid. The production fluid contains a concentration of the constituting material in the range between] and 0.01 and 5%. The constituent(s) of the final microspheres are dissolved in the production fluid. As a nozzle an ink-jet head is employed that is placed under the surface of the receiving liquid/air interface. In this configuration inkjetted droplets do not have to pass the air-liquid interface but will be injected directly into the receiving fluid.

Description

SYSTEM FOR MANUFACTURING MICRO-SPHERES
The invention pertains to a system for manufacturing micro-spheres from a production fluid.
Such a system is known from the paper 'Uniform Paclitaxel-loaded biodegradable microspheres manufactured by ink-jet technology' in Proc. Recent Adv. in Drug Delivery Sys. (March 2003) by D. Radulescu et al.
The known system produces biodegradable microspheres, i.e. micro-spheres on the basis of ink-jet technology. In particular paclitaxel loaded PLGA microspheres of narrow size distribution and controlled diameter are manufactured. The known system employs a drop-on-demand process or pressure assisted drop-on-demand for jetting a paclixatel PLGA mixture into an aqueous polyvinyl alcohol solution. Microspheres having a narrow size distribution around όOμm±lμm have been produced. These micro-spheres are formed from a dichloroethane solution containing 3% of PLGA and 1.5% of paclitaxel. After making drops of this solution the dichloroethane is removed and solid particles containing a mixture of PLGA and paclitaxel remain.
An object of the invention is to provide a system to manufacturing micro- spheres having far smaller sizes than the size of the microspheres produced by the known system and also achieving narrow size distribution.
The invention is based on the insight mat starting from low concentration, i.e. in the range of 0.01% to 5%, from polymers monodisperse, dense polymer particles can be formed by inkjetting and subsequent removal of solvent. Good results are achieved in the range of polymer concentration of 0.01 to 3%. Particularly reliable formation of monodisperse microspheres is achieved in the range of polymer concentration of 0.01 to 2.9%.The size of the micro-spheres bubbles is very small, notably micro-spheres having size in the range l-15μm, with a small variation in volume of about 3% is achieved. Typically 5 μm sized micro-spheres are produced. The production fluid is a solution of the constituting material, i.e. the material(s) of which the microspheres are to be made in a solvent. In other words: the constituent(s) of the final microspheres are dissolved in the production fluid. For example in the solvent polymer or monomers may be dissolved. The solvent in the production fluid should have a limited solubility in the receiving fluid with the receiving fluid. The solvent will slowly diffuse into the receiving fluid and subsequently evaporate, leading to shrinkage of the drops of the production fluid. Good results are achieved at solubilities around 1%, such as is the case for dichloroethane (DCE ) or dichloroomethane (DCM) in water.
Good maintenance of the size and distribution of the size of the micro-spheres is in particular achieved when the micro-spheres form a stable colloid, which is facilitated by the presence of polymers or surfactant in the receiving fluid. Then coalescence of droplets into larger droplets is counteracted/prevented. In a preferred embodiment the production liquid contains a halogenated solvent which has a high density, such as dichloro-ethane and the receiving solution is aqueous. Halogenated solvents with a small solubility in water (about 0.8% for dichloroethane) and a high vapour pressure are preferred for slow and controlled removal from the drops of production fluid. The constituents of the final microspheres are dissolved in the production fluid. For constituents to be used (intravenously) inside living humans, biodegradable polymers and (modified) phospholipids are preferred as carrier materials, drugs and imaging agents can be incorporated in the microspheres and targeted to markers of diseases expressed on blood vessel walls, such as markers for angiogenesis associated with tumours and markers for vulnerable plaques. After jetting, the excess stabilizer can be removed through a series of washing steps and the removal of the final remainders of the halogenated solvent can be established by lyophilization (freeze drying). It appears an essentially monodisperse distribution of small sized microspheres is achieved. The jetting of the production fluid into the receiving fluid leads to better excellent separation of the individual micro-droplets when they leave the nozzle. The manufacturing involves jetting of the production fluid at relatively high jetting rates, into a receiving fluid. It is found that at low polymer concentration in the production fluid, shrinkage of the droplet to essentially non-porous polymer micro-spheres occurs.
As the method outlined above leads to dense particles, it will also lead to dense shells, therefore giving a robust encapsulation of liquids or gases. To achieve this the production liquid has to be modified with a non-solvent for the shell forming material. The production liquid can also be modified to include phospholipids rather than polymers or a combination of phospholipids and polymers.
According to another aspect of the invention the system for manufacturing micro-spheres is provided with a control system to operate the jetting in a pulsed fashion. The control system control the application of excitation pulses to the jetting module. Block shaped pulses achieve good results in that somewhat larger sized micro-spheres of a few tenths of nl volume are produced.
According to a further aspect of the invention, the jetting system is provided with several nozzles that can be individually controlled to adjust the sizes of the micro- bubbles from the respective nozzles. For example, these nozzles are controlled so that they all produce bubbles within a narrow size distribution. The individual control of the individual nozzles then compensates for small differences between the nozzles. Notably, this is achieved by adjusting the electrical activation pulses applied to the nozzles. In particular, the width of the volume distribution can be narrowed to about 3-5%. As more nozzles are employed, more micro-spheres can be produced per unit of time.
According to another aspect of the invention, micro-spheres with a controlled porosity can be formed. According to a further aspect of the invention, the reservoir is provided with a temperature control to cool the receiving fluid below its condensation temperature. Good results are achieved when the receiving liquid is cooled below room temperature, i.e. below 298K. Then, the production fluid is jetted in the form of droplets into the cooled receiving liquid, and may be stored for later use. When the temperature of the droplets is raised, the receiving fluid is evaporated and gas-filled micro-spheres are formed. Further a catalyst may be employed in the receiving liquid to initiate polymerization of the production fluid to enhance formation of stable micro-bubbles. As an alternative irradiation with electro-magnetic radiation, for example ultra-violet radiation of the bubbles leaving the nozzle by means of an irradiation module may be employed for photo-initiation of polymerization.
In another aspect of the invention one can make use of the lower critical solution temperature (LCST) or upper critical solution temperature (UCST) of polymers. An LCST is observed when precipitation of the polymer occurs at increasing temperatures. Thus, for production of micro-spheres, the temperature of the receiving fluid is raised above the LCST and the polymer containing solution is jetted at temperature below the LCST. Micro¬ spheres will then form due to the precipitation of the polymer within the well-defined droplets. This approach is particular advantageous when use of halogenated receiving liquids is not allowed, or when lyophilization (freeze-drying) is not desired. Example of a well- known polymer with an LCST is poly(N-isopropylacryl amide)(PNiPAAm). The LCST of this polymer (~ 32 °C) can be easily tuned to relevant temperatures for clinical application (e.g. below or above 37 0C) by copolymerisation with poly(acrylic acid) or more hydrophobic acrylates, depending on the LCST desired.
When the droplets are jetted into air, instead of directly into the receiving liquid , then employing a long flight path - e.g. of a few centimeters- from the nozzle for the droplets also leads to formation of micro-spheres.
According to one aspect of the invention the ink-jet head is placed under the surface of the receiving liquid/air interface. In this configuration inkjetted droplets do not have to pass the air- liquid interface but will be injected directly into the receiving fluid. Using this configuration the stabilizing action of polymers or surfactants present in the receiving liquid will be optimized leading to a stable emulsion of drops of the production fluid in the receiving liquid. Alternatively, the stabilizer can be added to the production fluid, a suitable stabilizer is a phospholipid. As an additional advantage of submerged inkjetting no problems associated with the surface characteristics of the receiving liquid will occur. Good emulsion and jetting stability are supported by the production fluid and the receiving liquid having different densities. If the production fluid has a higher density than the receiving liquid and the jet is in the direction of gravity, the droplet will continue to sink to the bottom of the container with their sedimentation velocity, from which they can be easily collected. In an alternative set-up the production fluid has a lower density than the receiving liquid and the droplets are jetted in a direction such that the droplets float towards the surface of the receiving liquid without returning towards the nozzle. The micro-spheres that are formed can then be collected at the surface of the receiving liquid. The invention also relates to an ultra-sound contrast agent. The use of apsherical microdroplets as an ultra-sound contrast agent is known per se from the US-patent US 5 606 973. The ultra-sound contrast of the invention comprises essentially mono-disperse micro-bubbles filled with a gas or monodisperse microspheres filled with fluorocarbonliquid. The micro-bubbles not only change the reflection of ultra sound, but also are able to resonate in the ultrasound field which yields harmonics. Such a mono-disperse contrast agent is in particular advantageous to be employed in the form of a targeted contrast agent. The targeted contrast agent selectively binds to specific receptors, e.g. adheres to vessel wall tissue. The resonance frequency of selectively bound micro-bubbles is shifted with respect to the non- bound micro-bubbles. The mono-disperse distribution of micro-bubbles leads to narrow line width of these resonances and hence the frequency shift can be detected. Hence, bound contrast agent can be accurately distinguished from unbound contrast agent.
Such gas filled bubbles can be prepared from a production fluid containing a halogenated solvent, a low concentration of shell forming biodegradable polymer, a second non-polar liquid with not too high a molecular weight which will allow for removal by lyophilization. Biodegradable polymers are chosen that are insoluble in the receiving liquid, but also insoluble in the production fluid if the halogenated solvent has disappeared by diffusion into the receiving liquid followed by evaporation. Upon lyophilization the second, non polar solvent is removed by sublimation leaving hollow particles Typical biodegradable polymers that can be used in the invention are biopolymers, such as dextran and albumin or synthetic polymers such as poly(L-lactide acid) (PLA)and certain poly(meth)acrylates polycaprolacton, polyglycolicacid Of particular importance are so-called (block)copolymers that combine the properties of both polymer blocks (e.g. hydrophobic and hydrophilic blocks). Examples of random copolymers are poly(L-lactic-glycolic acid)(PLGA) and poly(d-lactic-l- lactic acid) Pd,lLA; Examples of diblock copolymers are poly(ethylene glycol)-poly(L-lactide) (PEG-PLLA), poly(ethylene glycol) - poly(N-isopropylacryl amide)(PEG-PNiPAAm)and poly(ethylene oxide)- poly(propylene glycol) (PEO-PPO). An example of a triblockcopolymer is poly(ethylene oxide)-poly(propylene glycol)-poly(ethyleneoxide) (PEO-PPO-PEO). Good results are achieved when a polymer, such as an L-polylactide, with a fluorinated end group, such as CeF14 is employed in the production fluid. For the preparation of hollow capsules this is especially advantageous. If the inside of a capsule is hydrophobic, there will be no tendency to the condensation of water vapour on the inside wall of the capsules. Therefore, the capsules will not fill up with water but remain gas-filled for long periods of time, which is desirable for an ultrasound contrast agent. Incorporating fluor containing groups in the polymer increases the hydrophobicity of the inside capsule wall, and therefore inhibits condensation. In addition the incorporation of fluor containing groups gives a more efficient diffusion barrier for water and polar solutes
The micro-spheres that result from this production liquid have a very good impermeability for water The synthesis of such fluorinated polymer is known per se from the US-patent US 6 329 470. The elasticity of the shell can be tuned by varying the polymer properties, the important parameters or the gel transition temperature and the maximum elongation before breakage of the a film made from the material will occur.
Micro-spheres filled with a liquid such as a fluorinated liquid, such as perfluorobromo-octane are not only useful for ultrasound but also for functional magnetic resonance imaging (fMRI). The technique of fMRI is generally disclosed in the Proc. Intl. Soc. mag. Reson. Med. 9(2001)659-660. In particular on then basis of the nucleus 19F magnetic resonance spectroscopy measurements can be made of tissue oxygenations, pharmacokinetics of fluorinated cancer drugs as mentioned per se in the Proc. Intl. Soc. mag. Reson. Med. 9(2001)497 They can be prepared as described above, except that fluorine containing non-polar liquid is chosen and that this liquid is not removed during lyophilization.
Micro-spheres can also be filled with drugs; drugs can be dissolved in an oil, and micro-spheres with a liquid core will be formed, or gaseous drugs can be incorporated by exposing micro-spheres to the gas containing the gaseous drug after lyophilization. The drugs can be used for controlled release, for instance release by an ultrasound pulse to effectuate local delivery. This will be most efficient when targeted micro-spheres are used.
Drugs can also be incorporated in (otherwise) dense micro-spheres. Notable radio-active compounds, such as (activated/chelated) Holmium compounds for the treatment of liver malignancies are useful. For example Holmium functions as a magnetic resonance contrast agent which induces Ti as well as T2 contrast. Further, Holmium can made radioactive by irradiating with neutrons. The radioactive isotopes of Holmium irradiate β- radiation (high-energy electronics) as well as γ-radiation. The β-radiation can be employed therapeutically to locally destroy tumours while the activity as magnetic resonance contrast agent enables monitoring of correct local application of the radioactive Holmium.
Additionally the γ-emission can be detected by a gamma-camera to image the anatomy where the Holmium is applied. Micro-spheres with non-radioactive Holmium are first formed and subsequently by irradiating with neutrons the Holmium in converted into radioactive Holmium isotopes in the micro-spheres. The Holmium should not be released until it has lost its radioactivity. Particle should be big enough to get trapped in the capillary bed and no fine micro-spheres should get a chance to circulate in the blood. For this reason a well controlled synthesis is required.
The typical size of the micro-spheres depends on the specific application. Preferred sizes range from 1 — 100 μm. For example micro-spheres for US imaging as blood- pool agents have most preferred diameters between 1- 10 μm. Most preferred diameters for Holmium encapsulated micro-spheres are within 15-40 μm.
These and other aspects of the invention are further elaborated with reference to the detailed examples and with reference to the accompanying drawing wherein
Figure 1 shows a diagrammatic representation of a system for manufacturing micro-bubbles of the invention;
Figure 2 shows the size distribution of inkjetted particle after washing with PVA, percentage of particle in 1 μm classes is given;
Figure 3 shows a SEM picture of PLA particles obtained according to the procedure described in Example 1 below and Figure 4 shows size distributions from examples 7 (0.1% plga) and 8 (0.1% plga, 0.3% cyclo-octane);
Figure 5 shows an example of microspheres made of an L_polylactide having a model diameter of 4.7μm;
Figure 6 shows an example of microspheres made of an L_polylactide having a model diameter of 4.5μm.
Figure 1 shows the diagrammatic representation of a system for manufacturing micro-bubbles of the invention. The system for manufacturing micro-bubbles comprises the reservoir 1 which contains the receiving fluid 11. A jetting system 2 includes a nozzle 21 to eject of jet droplets of the production fluid 23 into the receiving fluid. The nozzle 21 is provided with a piezo-electrical system 22 that applies pressure pulses to the nozzle to produce the droplets 24 from which the micro-spheres 25 form that assemble in this example at the bottom of the reservoir 1. For example the nozzle 21 may be configured an ink-jetting head.
The jetting system 2 is also provided with a control unit 3 which applies electrical pulses to the piezo-electrical system 22. The control unit in this way controls the operation of the jetting system to produce the droplets of the production fluid. Further, a cooling system 4 is provided, in this example in the form of a jacket 4 through which a cooling fluid, e.g. water, is passed from an inlet 41 to an outlet 42. The cooling system operates to cool the receiving liquid to below room temperature.
Additionally, the system for manufacturing micro-bubbles is provided with an ultraviolet radiation source 5, which emits a (pulsed) beam of ultraviolet radiation to the droplets of production fluid from the nozzle to cause photoinitiasation of polymerization in the droplets in order that micro-spheres are formed.
Examples: Example 1, preparation of 10 mm PLA particles
A 1% PLA (poly-DL-lactide, Aldrich) solution in dichloroethane was inkjetted, starting immediately after immersion of the ink jet head into an aqueous 1% PVA (15/79) solution in a fluorescence cuvet. The initial drop diameter is about 50 μm as observed through the cuvet, which corresponds to a drop volume of 6.5*10-14 m3. After inkjetting for 20 minutes at 1500 Hz, the procedure was stopped. The sediment was redispersed and transferred to a glass sample bottle and stirred for one hour to remove the dichloroethane. The particles were washed 3 times with filtered (200 nm), deionised water. A sample was taken for microscopic examination, revealing well dispersed spherical particles with a diameter of about 10 μm. The size distribution obtained from microscopic examination using a 2Ox objective and image pro plus software to analyze the mean diameter is given in Figure 2. The sample was freeze dried for 48 hours and stored at -20°C. SEM pictures, taken after redispersion in filtered deionised water, drying and deposition of a 3 nm Pd/Pt layer, show a particle size of 10.2 ± 0.3 μm which corresponds to a particle volume of 5.6*10-16 m3. As the densities of dichloroethane and PLA are approximately equal, the volume ratio between initial and final size demonstrates that PLA particles have been prepared with a low porosity. An SEM picture of the particles produced is given in Figure 3.
Example 2, preparation of 18 mm PLA particles
A 3% PLA (poly-DL-lactide, Aldrich) solution in dichloroethane was inkjetted, starting immediately after immersion of the ink jet head into a aqueous 1% PVA solution in a fluorescence cuvet. After inkjetting for 20 minutes at 1500 Hz, the procedure was stopped. The sediment was redispersed and transferred to a glass sample bottle and stirred for one hour to remove the dichloroethane. The particles were washed 3 times with filtered (200 nm), deionised water. A sample was taken for microscopic examination, revealing well dispersed monodisperse spherical particles with a diameter of about 18 μm. Freeze drying did not change the particle size. The volume ratio between initial droplet volume and final particle size is 20, which is expected for a 5% solution if completely dense polymer particles would have formed. This indicates that remaining porosity is present in these prepared particles made from a 3% solution.
Example 3, preparation of PLGA particles
A 3% PLGA (PoIy-DL lacticde-co-glycolide (75:25), Aldrich) solution in dichloroethane was inkjetted, starting immediately after immersion of the ink jet head into a aqueous 1% PVA solution in a fluorescence cuvet. After inkjetting for 20 minutes at 1500 Hz, the procedure was stopped. The sediment was redispersed and transferred to a glass sample bottle and stirred for one hour to remove the dichloroethane. The particles were washed 3 times with filtered (200 nm), deionised water. A sample was taken for microscopic examination, revealing well dispersed monodispersed spherical particles with a diameter of about 18 mm. Freeze drying did not change the particle size. The volume ratio between initial droplet volume and final particle size is 20, which is expected for a 5% solution if completely dense polymer particles would have formed. This indicates that remaining porosity is present in these prepared particles made from a 3% solution.
Example 4, preparation of pla particles using continuous inkjet
A 1% solution of pla in dichloroethane was prepared and inkjetted into a 1% aqueous PVA 15/79 solution at a frequency of 14 kHz using a 50 μm nozzle. After evaporation of dichloroethane, washing and freeze-drying particles with an average diameter of 15.3 μm and a standard deviation of 2.7 μm were formed as quantified using image analysis of optical microscopy pictures.
Example 5, Preparation of pla particles loaded with Holmium-acetylacetonate
A 1% solution of pla, 0.02% of holmium-acetylacetonate in dichloroethane was inkjetted into a 1% aqueous PVA (15/79) solution at a frequency of 14 kHz using a 50 μm nozzle. The particles formed after evaporation of dichloroethane, washing and freeze- drying had an average diameter of 15.7 μm and a standard deviation of 2.6 μm as quantified using image analysis of optical microscopy pictures.
Example 6, Preparation of 12 mm plga particles by continuous inkjet A 1% solution of plga (75% lactic acid, 25% glycolic acid) in dichloroethane was prepared and inkjetted into a 1% PVA 15/79 solution at a frequency of 14 kHz using a 50 μm nozzle. The particles formed after evaporation of dichloroethane, washing and freeze- drying had an average diameter of 12.5 μm and a standard deviation of 2.3 μm as quantified using image analysis of optical microscopy pictures.
Example 7, preparation of 7 mm plga particles by continuous inkjet
A 0.1% solution of plga (75% lactic acid, 25% glycolic acid) in dichloroethane was prepared and inkjetted into a 1% PVA 15/79 solution at a frequency of 14 kHz using a 50 μm nozzle. The particles formed after evaporation of dichloroethane, washing and freeze- drying had an average diameter of 6.8 μm and a standard deviation of 1.3 μm, as quantified using image analysis of optical microscopy pictures. The size distribution is indicated in Figure 4.
Example 8, preparation of 11 micron polymer-shelled capsules
A 0.1% solution of plga and 0.3% of cyclo-octane ) in dichloroethane was prepared and inkjetted into a 0.1% PVA 40/88 solution at a frequency of 14 kHz using a 50 μm nozzle. Dichloroethane was evaporated, the sample was washed with water previously saturated with cyclo-octane, and freeze-dried. Capsules with a diameter of 11.2 μm with a standard deviation of 1.8 μm were formed, as quantified using image analysis of optical microscopy pictures, the size distribution is indicated in Figure 4. Capsules had a smooth surface contained one single cavity as deduced from SEM pictures.
Example 9, preparation of lipid-coated capsules A 0.1% plga, 0.3% cyclooctane, 0.005% asolectin in dichloroethane was inkjetted into an aqueous PVA 15/79 solution at 12 kHz using a 50 μm nozzle. The dichloroethane was evaporated, the sample was washed and freeze dried, smooth capsules with a diameter of 7.5 μm were observed using SEM exhibiting a single hollow core.
Example 10
An L-polylactide having a C6FH end group was dissolved at a concentration of 0.01% in dichloroethane in the presence of 0.01% cyclodecane. Using submerged inkjetting in 0.3% pva with a 50 μm nozzle at a frequency of 23,000 Hz droplets were formed with an initial diameter of about 85 μm. By repeated washing and stirring overnight the droplets shrank to form cyclodecane filled capsules with a modal diameter of 4.7 μm. The size distribution was measured on a Coulter Counter and is given in Figure 5. The sample was lyophilised to remove the core of cyclodecane, the size distribution after removal and redispersion is unchanged as shown in Figure 5. Microscopy on redispersed samples showed gas filled capsules. Upon exposure to ultrasound the escape of gas could be detected
Example 11
An L-polylactide having a C6FH end group was dissolved at a concentration of 0.005% in dichloroethane in the presence of 0.01% cyclodecane. Using submerged inkjetting in o.3% pva with a 50 μm nozzle at a frequency of 23,000 Hz droplets were formed with an initial diameter of about 85 μm. By repeated washing and stirring overnight the droplets shrank to form cyclodecane filled capsules with a modal diameter of 4.5 μm. The size distribution was measured on a Coulter Counter and is given in Figure 6. The sample was lyophilised to remove the core of cyclodecane, the size distribution after removal and redispersion is hardly changed as shown in Figure 6. Microscopy on redispersed samples showed gas filled capsules. Upon exposure to ultrasound the escape of gas could be detected.

Claims

CLAIMS:
1. System for manufacturing micro-spheres of a production fluid (23)containing a constituting material, the system comprising
- a reservoir (1) for holding a receiving fluid (11) - a jetting module (2) having at least one nozzle (21) for jetting the production fluid into the receiving fluid, wherein
- the production fluid contains a concentration of the constituting material in the range between 0.01% and 5%.
2. A system for manufacturing micro-spheres as claimed in Claim 1 including a control system to control the jetting at a jetting rate in the range of 100kHz"1 to 0.IkHz"1
3. A system for manufacturing micro-spheres as claimed in Claim 2, wherein the control system is arranged to operate the jetting in a pulsed fashion, in particular the control system being arranged to apply block form excitation pulses to the jetting module.
4. A system for manufacturing micro-bubbles as claimed in Claim 1, wherein
- the jetting system includes several nozzles and
- the control system is arranged to adjust the droplet-sizes for the individual nozzles
5. A system for manufacturing micro-spheres as claimed in Claim 1, wherein the reservoir is provided with a temperature control system.
6. A system for manufacturing micro-bubbles as claimed in Claim 1, including an irradiation module to irradiate the micro-bubbles with electro-magnetic radiation of which the wavelength is in the range of 200-800 nm ....
7. A system for manufacturing micro-bubbles as claimed in Claim 1, wherein a flight path of the micro-bubbles extends from the nozzle into the receiving fluid over a distance.
8. A system for manufacturing micro-spheres as claimed in Claim 1, wherein the receiving liquid and or the production fluid contains a stabilizer from the group of lipids, surfactants, polymers or block copolymers.
9. An ultra-sound contrast agent comprising essentially monodisperse micro- bubbles.
10. An ultrasound contrast agent as claimed in Claim 9 targeted to a specific location in the vasculature, in particular targeted for thrombosis, vulnerable plaque or angiogenesis.
11. An ultrasound contrast agent as claimed in Claim 9 modified with antibodies, antibody fragments or (other) peptides.
12 . An MR-contrast agent comprising essentially monodisperse micro-bubbles, in particular containing a 19F compound.
13. An encapsulated drug comprising essentially monodisperse micro-bubbles loaded with a pharmaceutical active compound for example active against diseases addressable from the vasculature, such as vulnerable plaque or thrombosis or cancer.
14. An encapsulated therapeutic compound comprising essentially monodisperse micro-bubbles loaded with a radioactive compound or a compound having radioactive isotopes, in particular Holmium.
EP05749229A 2004-06-29 2005-06-24 System for manufacturing micro-spheres Ceased EP1763397A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05749229A EP1763397A1 (en) 2004-06-29 2005-06-24 System for manufacturing micro-spheres

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04103038 2004-06-29
PCT/IB2005/052098 WO2006003581A1 (en) 2004-06-29 2005-06-24 System for manufacturing micro-spheres
EP05749229A EP1763397A1 (en) 2004-06-29 2005-06-24 System for manufacturing micro-spheres

Publications (1)

Publication Number Publication Date
EP1763397A1 true EP1763397A1 (en) 2007-03-21

Family

ID=34970671

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05749229A Ceased EP1763397A1 (en) 2004-06-29 2005-06-24 System for manufacturing micro-spheres

Country Status (5)

Country Link
US (1) US20080019904A1 (en)
EP (1) EP1763397A1 (en)
JP (1) JP5068646B2 (en)
CN (1) CN1984708B (en)
WO (1) WO2006003581A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007014876A (en) * 2005-07-07 2007-01-25 Nippon Kayaku Co Ltd Production method of particulate type curing catalyst
US8257338B2 (en) * 2006-10-27 2012-09-04 Artenga, Inc. Medical microbubble generation
JP2009524602A (en) * 2006-01-24 2009-07-02 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ Method for producing particles including gas core and shell, and particles obtained by the method
WO2007105047A2 (en) * 2006-03-10 2007-09-20 Mcgill University Ultrasound molecular sensors and uses thereof
CA2702367C (en) * 2007-10-12 2012-08-21 Fio Corporation Flow focusing method and system for forming concentrated volumes of microbeads, and microbeads formed further thereto
EP2055299A1 (en) 2007-10-23 2009-05-06 Koninklijke Philips Electronics N.V. Methods for preparing polymer microparticles
WO2009053885A2 (en) * 2007-10-23 2009-04-30 Koninklijke Philips Electronics N.V. Methods for preparing polymer microparticles
GB2455143A (en) * 2007-11-30 2009-06-03 Ct Angewandte Nanotech Can Preparation of emulsions using inkjet technology
EP2103313A1 (en) * 2008-03-19 2009-09-23 Koninklijke Philips Electronics N.V. Method for the synthesis of hollow spheres
EP2318086B1 (en) * 2008-07-23 2016-04-13 Koninklijke Philips N.V. Ultrasound mediated drug delivery
GB2469087A (en) * 2009-04-02 2010-10-06 Ct Angewandte Nanotech Can Preparation of colloidal dispersion
WO2011135275A1 (en) * 2010-04-29 2011-11-03 Imperial Innovations Limited Method and microbubbles for detecting atherosclerotic plaque
GB201016436D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Method of making solid beads
GB201016433D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Apparatus and method for making solid beads
KR20130136557A (en) * 2011-04-11 2013-12-12 인텔 코오퍼레이션 Personalized advertisement selection system and method
US20140294944A1 (en) 2013-03-28 2014-10-02 Kimberly-Clark Worldwide, Inc. Microencapsulation of oxygen liberating reactants
GB2551944B (en) * 2015-12-18 2021-09-01 Midatech Pharma Wales Ltd Microparticle production process and apparatus
WO2017220615A1 (en) 2016-06-20 2017-12-28 Virbac Method and apparatus for preparing a micro-particles composition
KR102613626B1 (en) * 2017-05-21 2023-12-15 엘지전자 주식회사 Fluid composition manufacturing apparatus
CN110833802A (en) * 2018-08-15 2020-02-25 漯河医学高等专科学校 Method for preparing magnetic starch microspheres by gamma-ray irradiation
CN114082376B (en) * 2022-01-10 2022-04-22 烟台科立化工设备有限公司 Polymer microsphere production device and production method

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
JPS607931A (en) * 1983-06-24 1985-01-16 Suriibondo:Kk Preparation of microcapsule
JPS61274738A (en) * 1985-05-29 1986-12-04 Mitsui Toatsu Chem Inc Microcapsule
JPH0558882A (en) * 1991-09-04 1993-03-09 Yoshiaki Kawashima Production of nanocapsule
GB9221329D0 (en) * 1992-10-10 1992-11-25 Delta Biotechnology Ltd Preparation of further diagnostic agents
JPH0775728A (en) * 1993-06-18 1995-03-20 Suzuki Yushi Kogyo Kk Production of uniform inorganic microbead
NO940711D0 (en) * 1994-03-01 1994-03-01 Nycomed Imaging As Preparation of gas-filled microcapsules and contrast agents for diagnostic imaging
US5540909A (en) * 1994-09-28 1996-07-30 Alliance Pharmaceutical Corp. Harmonic ultrasound imaging with microbubbles
US6139819A (en) * 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
US5606973A (en) 1995-06-07 1997-03-04 Molecular Biosystems, Inc. Liquid core microdroplets for ultrasound imaging
US6368586B1 (en) * 1996-01-26 2002-04-09 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
US5873811A (en) * 1997-01-10 1999-02-23 Sci-Med Life Systems Composition containing a radioactive component for treatment of vessel wall
GB2340040B (en) * 1997-04-30 2001-11-28 Point Biomedical Corp Microparticles useful as ultrasonic contrast agents and for delivery of drugs into the bloodstream
DE19800294A1 (en) * 1998-01-07 1999-07-08 Mueller Schulte Detlef Dr Inductively heatable polymer encapsulated magnetic particles for coupling bio-ligands
DE19925311B4 (en) * 1999-05-27 2004-06-09 Schering Ag Multi-stage process for the production of gas-filled microcapsules
AU7742600A (en) * 1999-09-30 2001-04-30 Research Foundation Of The State University Of New York, The Fluorocarbon end-capped polymers and method of synthesis
JP4029252B2 (en) * 2000-02-24 2008-01-09 セイコーエプソン株式会社 Microcapsule manufacturing method and display device manufacturing method
JP2005513081A (en) * 2000-12-13 2005-05-12 パーデュー・リサーチ・ファウンデイション Microencapsulation of drugs by solvent exchange
DE10105156A1 (en) * 2001-02-06 2002-08-22 Bruske Frank Method and device for producing particles from liquid starting media
US6919068B2 (en) * 2002-05-17 2005-07-19 Point Biomedical Corporation Method of preparing gas-filled polymer matrix microparticles useful for echographic imaging

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO2006003581A1 *

Also Published As

Publication number Publication date
WO2006003581A1 (en) 2006-01-12
CN1984708A (en) 2007-06-20
CN1984708B (en) 2014-01-29
JP5068646B2 (en) 2012-11-07
US20080019904A1 (en) 2008-01-24
JP2008504950A (en) 2008-02-21

Similar Documents

Publication Publication Date Title
US20080019904A1 (en) System For Manufacturing Micro-Sheres
Böhmer et al. Preparation of monodisperse polymer particles and capsules by ink-jet printing
US6767637B2 (en) Microencapsulation using ultrasonic atomizers
Chang et al. Controlling the thickness of hollow polymeric microspheres prepared by electrohydrodynamic atomization
JP5733981B2 (en) Method and device for preparing polymer microparticles
Song et al. Controllable formation of monodisperse polymer microbubbles as ultrasound contrast agents
ES2223080T5 (en) MICROENCAPSULATED GASES IN A POLYMER AND A LIPID FOR USE AS VISUALIZATION AGENTS.
TWI246426B (en) Microencapsulated fluorinated gases for use as imaging agents
JP2011506271A5 (en)
US20080213355A1 (en) Method and System for in Vivo Drug Delivery
BRPI0707150A2 (en) Method and Equipment for Wireless Video Communication Error Resilience Algorithms
Xia et al. Uniform biodegradable microparticle systems for controlled release
WO2003099112A1 (en) Microparticles having a matrix interior useful for ultrasound triggered delivery of drugs into the bloodstream
JP2008528268A (en) Method and apparatus for obtaining micrometer and nanometer size particles
JP2008517997A (en) Dispersion formulation of particles for use as a contrast agent in ultrasound imaging
US20170189569A1 (en) Biodegradable microspheres incorporating radionuclides technical field
Singh et al. Design and evaluation of microspheres: A Review
ES2284776T3 (en) MICROPARTICLES.
US20090196827A1 (en) Drug Loaded Contrast Agents: Combining Diagnosis and Therapy
Chang et al. A novel process for drug encapsulation using a liquid to vapour phase change material
WO2007085990A1 (en) Method for producing a particle comprising a gas core and a shell and particles thus obtained
EP3615090A1 (en) Biodegradable microspheres incorporating radionuclides
Grinberg et al. Encapsulating bioactive materials in sonochemically produced micro-and nano-spheres
Chang et al. Ultrasound mediated release from stimuli-responsive core–shell capsules
EP2205220A1 (en) Methods for preparing polymer microparticles

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070129

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20120723

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: KONINKLIJKE PHILIPS N.V.

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20170206